May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Experimental Model of LASIK and Pharmacological Modulation of Corneal Transparency
Author Affiliations & Notes
  • R.M. Torres
    IOBA, Valladolid, Spain
  • J.M. Merayo–Lloves
    IOBA, Valladolid, Spain
  • J.T. Blanco–Mezquita
    IOBA, Valladolid, Spain
  • S. Mar
    Physics and Optics Applied, Valladolid, Spain
  • C.P. Günther
    IOBA, Valladolid, Spain
  • G. Rodríguez
    IOBA, Valladolid, Spain
  • A. Mayo
    IOBA, Valladolid, Spain
  • C. Martínez–García
    Biology Department, Valladolid, Spain
  • Footnotes
    Commercial Relationships  R.M. Torres, None; J.M. Merayo–Lloves, None; J.T. Blanco–Mezquita, None; S. Mar, None; C.P. Günther, None; G. Rodríguez, None; A. Mayo, None; C. Martínez–García, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2173. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.M. Torres, J.M. Merayo–Lloves, J.T. Blanco–Mezquita, S. Mar, C.P. Günther, G. Rodríguez, A. Mayo, C. Martínez–García; Experimental Model of LASIK and Pharmacological Modulation of Corneal Transparency . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2173.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Develop an experimental animal model of LASIK and assess pharmacological modulation of cornel transparency with an objective method. Methods: 32 adult hens were cared follow ARVO guidelines, underwent LASIK surgery (right eyes) and were divided in 4 groups with different post–operative treatment: A– no treatment; B– carboxymethyl chitosan 0.5%; C– carmellose sodium 0.5%; D– fluorometholone 0.20%. Left eyes from group A were used as control (no surgery, no drugs): group E. Masked treatments were applied for 10 days. Surgical procedure: animals were anesthetised (intramuscular and topical) and corneal flaps were created with a special microkeratome (60 µm plate). Stromal photoablation was performed with a 193nm excimer laser, programmed for –4D. Surgical outcome and follow up was performed 1, 15 and 30 days after surgery, with a surgical microscope, and haze was clinically evaluated (grade 0–4). Day 30, animals were euthanasized, corneas were carefully excised and corneal transmittance was objectively assessed with an experimental scatterometer. Corneal tissue was fixed for light microscopy study. Results: Surgical outcome shows intra–operative (12.5%) and postoperative (18.7%) complications and these animals were excluded from the study. Haze was not clinically detected in the 22 eyes (68.7%) that finished the study. The higher corneal transmittance value was found in group E and lower in group B. Statistically significance difference was not found between groups B, C and D (treated groups) but significance difference (P < 0.05) was found between groups B, C comparing that with group E. Conclusions: an experimental animal model of LASIK was developed and was used to assess pharmacological modulation of corneal transparency, which was evaluated with an objective method. Corneal transparency shows no differences between treated groups.

Keywords: refractive surgery: LASIK • cornea: stroma and keratocytes • refractive surgery: complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.